Report period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
End date of the reporting period | ||||||
Capitalization, $ | ||||||
Capitalization, $ | ||||||
Enterprise Value | ||||||
Book Value | ||||||
Shareholders Book Value | ||||||
Current liabilities | ||||||
Noncurrent liabilities | ||||||
Total liabilities | ||||||
Debt | ||||||
Cash and cash equivalents | ||||||
Net debt | ||||||
Assets | ||||||
Total ordinary shares | ||||||
Ordinary share price |
Ticker | Name | Type | Nominal value | ISIN | Price |
---|---|---|---|---|---|
MRK:US | Merck & Company Inc. (new) | Common share | - | US58933Y1055 | $123.8 |
MRK-RM:RM | Merck & Co | Common share | $0.5 | US58933Y1055 | RUB 4,821 |
Date | Type | Note | Source |
---|---|---|---|
05.04.2024 10:00 | Dividends | The company will pay dividends of $0.77 per common share for Q2 Fiscal Year 2024. | www.merck.com |
Company name | Merck & Company |
---|---|
Tags | #pharmacy, #s&p500 index |
Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals |
Business address | 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 908-740-4000 |
Mailing address | 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 |
Website | investors.merck.com |
Information disclosure | www.sec.gov |